Open AccessReal‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID‐19) pandemic: A case series
Author(s) -
Vijayan Sooraj,
Hwangbo Kyungmin,
Barkham Nick
Publication year - 2022
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.5233
Subject(s) - ankylosing spondylitis , medicine , infliximab , pandemic , covid-19 , disease , spondylitis , coronavirus , virology , infectious disease (medical specialty) , outbreak
The COVID‐19 pandemic emphasized the utility of subcutaneous (SC) biologics for pressured healthcare systems. The first SC form of infliximab, CT‐P13 SC, provided safe and effective treatment for ankylosing spondylitis in our case series, with increased convenience relative to intravenous treatment benefitting patients both during the pandemic and beyond.